Alumis Inc. Common Stock
Financials
Valuation Metrics
Alumis Inc. Common Stock's Market Cap is $859M. At end of 2025 it was $1.02B. Ranked #2489 of 3,116 in US market (top 80%), #1030 of 1,472 on NASDAQ (top 70%), #189 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 71%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $859M | US#2,489/3,116 Sec#189/265 |
| Revenue | $7M | US#2,811/3,116 Sec#171/265 |
| Net Income | $-439M | US—/3,116 Sec—/265 |
| Total Assets | $561M | US#2,716/3,116 Sec#149/265 |
| Net Assets | $452M | US#2,286/3,116 Sec#118/265 |
| Employees | 226 | US#2,461/3,116 Sec#125/265 |
| Value | ||
| P/B | 1.90x | US#1,217/3,116 Sec#54/265 |
| P/S | 116.15x | US#2,948/3,116 Sec#182/265 |
| FCF Yield | -40.94% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -97.08% | US#2,777/3,116 Sec#201/265 |
| ROA | -78.30% | US#3,036/3,116 Sec#246/265 |
| Op. Margin | -6204.39% | US#2,837/3,116 Sec#181/265 |
| Revenue Growth | -63.11% | US#2,705/3,116 Sec#165/265 |
| Financial Health | ||
| Debt Ratio | 23.99% | US#266/3,116 Sec#88/265 |
| Total Debt | $36M | US#2,656/3,116 Sec#168/265 |
| FCF | $-352M | US#2,867/3,116 Sec#241/265 |
| Cash | $64M | US#2,464/3,116 Sec#208/265 |
| Current Ratio | 6.74x | US#361/3,116 Sec#113/265 |
| Performance | ||
| 1Y Return | 44.64% | US#555/3,116 Sec#80/265 |
| 1M Return | -8.80% | US#2,322/3,116 Sec#166/265 |
| From 52W High | -78.50% | US#3,042/3,116 Sec#250/265 |
| 1Y MDD | -80.00% | US#3,038/3,116 Sec#245/265 |
| Trading | ||
| Volume | 1,758,169 shares | US#707/3,116 Sec#60/265 |
| Trading Value | $12M | US#1,939/3,116 Sec#150/265 |
| Per Share | ||
| EPS | $-3.44 | US—/3,116 Sec—/265 |
| BPS | $3.55 | US#2,407/3,116 Sec#149/265 |
Company Info
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.